

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/177890>

Please be advised that this information was generated on 2018-07-07 and may be subject to change.

Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey

Francesco Sardanelli^{1,2}  · Hildegunn S. Aase³ · Marina Álvarez⁴ · Edward Azavedo⁵ · Henk J. Baarslag⁶ · Corinne Balleyguier⁷ · Pascal A. Baltzer⁸ · Vanesa Beslagic⁹ · Ulrich Bick¹⁰ · Dragana Bogdanovic-Stojanovic¹¹ · Ruta Briediene¹² · Boris Brkljacic¹³ · Julia Camps Herrero¹⁴ · Catherine Colin¹⁵ · Eleanor Cornford¹⁶ · Jan Danes¹⁷ · Gérard de Geer¹⁸ · Gul Esen¹⁹ · Andrew Evans²⁰ · Michael H. Fuchsjaeger²¹ · Fiona J. Gilbert²² · Oswald Graf²³ · Gormlaith Hargaden²⁴ · Thomas H. Helbich⁸ · Sylvia H. Heywang-Köbrunner²⁵ · Valentin Ivanov²⁶ · Ásbjörn Jónsson²⁷ · Christiane K. Kuhl²⁸ · Eugenia C. Lisencu²⁹ · Elzbieta Luczynska³⁰ · Ritse M. Mann³¹ · Jose C. Marques³² · Laura Martincich³³ · Margarete Mortier³⁴ · Markus Müller-Schimpfle³⁵ · Katalin Ormandi³⁶ · Pietro Panizza³⁷ · Federica Pediconi³⁸ · Ruud M. Pijnappel³⁹ · Katja Pinker⁸ · Tarja Rissanen⁴⁰ · Natalia Rotaru⁴¹ · Gianni Saguatti⁴² · Tamar Sella⁴³ · Jana Slobodníková⁴⁴ · Maret Talk⁴⁵ · Patrice Taourel⁴⁶ · Rubina M. Trimboli² · Ilse Vejborg⁴⁷ · Athina Vourtsis⁴⁸ · Gabor Forrai⁴⁹

Received: 14 June 2016 / Revised: 29 August 2016 / Accepted: 15 September 2016 / Published online: 2 November 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrat-

ed to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for

✉ Francesco Sardanelli
francesco.sardanelli@unimi.it

¹ Department of Biomedical Sciences for Health, University of Milan, Milan, Italy

² Department of Radiology, Research Hospital Policlinico San Donato, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy

³ Department of Radiology, Haukeland University Hospital, Jonas Lies vei 65, 5021 Bergen, Norway

⁴ Department of Radiology, Reina Sofia Hospital, Avda. Menéndez Pidal, s/n 14004 Córdoba, Spain

⁵ Department of Radiology, Karolinska University Hospital, Karolinska vägen, 171 76 Solna, Stockholm, Sweden

⁶ Department of Radiology, Meander Medical Center, Maatweg 3, 3813 Amersfoort, The Netherlands

⁷ Department of Radiology, Gustave-Roussy Institute, 114 Rue Edouard Vaillant, 94800 Villejuif, France

⁸ Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna/Vienna General Hospital, Währinger Gürtel 18-20, 1090 Wien, Austria

⁹ Clinic of Radiology, University Clinical Center Sarajevo, Bolnička 25, 71000 Sarajevo, Bosnia and Herzegovina

women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.

Key points

- *EUSOBI and 30 national breast radiology bodies support screening mammography.*
- *A first priority is double-reading biennial mammography for women aged 50–69 years.*
- *Extension to 73–75 and from 40–45 to 49 years is also encouraged.*

- *Digital mammography (not film-screen or computer radiography) should be used.*
- *DBT is set to become “routine mammography” in the screening setting in the next future.*

Keywords Breast cancer · Population-based screening · Digital mammography · Digital breast tomosynthesis (DBT) · Recall rate

Introduction

This position paper on screening for breast cancer (BC) has been proposed by the Executive Board and the Scientific Committee of the European Society of Breast Imaging (EUSOBI) and approved by 30 national breast radiology bodies/sections (Table 1). The aim is to give a clear message in favour of screening mammography to national/local governments, policy makers, referring physicians and the general population.

Breast cancer as a major health issue and the role of mammography in early diagnosis

All over the world, BC remains a major issue for public health. Increasing numbers of new cases and deaths are observed in both developed and less developed countries, only partially attributable to the increasing population age. In the 28 member

¹⁰ Clinic of Radiology, Charité, Universitätsmedizin Berlin, 10117 Berlin, Germany

¹¹ Diagnostic Imaging Center, Institute of Oncology, Institutski put 4, 21204 Sremska Kamenica, Serbia

¹² Radiology Department, National Cancer Institute, Santariskiu 1, Vilnius University, Vilnius, Lithuania

¹³ Department of Diagnostic and Interventional Radiology, University Hospital ‘Dubrava’, University of Zagreb School of Medicine, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia

¹⁴ Department of Radiology, Hospital de la Ribera, Carretera de Corbera, Km. 1, 46600 Alzira, Valencia, Spain

¹⁵ Radiology Unit, Hospices Civils de Lyon, Centre Hospitalo-Universitaire Lyon Sud, 165 Chemin du Grand Revoyet, 69495 Pierre Bénite Cedex, France

¹⁶ Nottingham Breast Institute, Nottingham University Hospitals, Hucknall Rd, Nottingham NG5 1PB, United Kingdom

¹⁷ Department of Radiology, Charles University in Prague, First Faculty of Medicine, U Nemocnice 2, 128 08 Praha 2, Czech Republic

¹⁸ Department of Radiology, ImageRive, Rue de Rive 1, 1204 Genève, Switzerland

¹⁹ Department of Radiology, Acibadem University Maslak Hospital, Buyukdere cd, Maslak, Sariyer, 34457 İstanbul, Turkey

²⁰ Dundee Cancer Centre, Clinical Research Centre, Ninewells Hospital, and Medical School, Tom McDonald Avenue, Dundee, UK

²¹ Division of General Radiology, Department of Radiology, Medical University Graz, Auenbruggerplatz 9, 8036 Graz, Austria

²² Department of Radiology, University of Cambridge, Cambridge Biomedical Campus, Hills Road CB2 0QQ, Cambridge, UK

²³ Institute of Radiology, ACC Steyr, Stadtplatz 30, 4400 Steyr, Austria

²⁴ Department of Radiology, Mater Misericordiae University Hospital/BreastCheck, BreastCheck, 36 Eccles St, Dublin 7, Ireland

²⁵ Referenzzentrum Mammographie Munchen, Sonnenstraße 29, 80331 Munich, Germany

²⁶ Diagnostic Department of Radiology, Tokuda Hospital Sofia, 1407 Sofia51B N Vaptsarov Blvd., Bulgaria

²⁷ Department of Radiology, Landspítali University Hospital, 108 Reykjavik, Iceland

²⁸ University Hospital of Aachen, Rheinisch-Westfälische Technische Hochschule, Pauwelsstraße 30, 52074 Aachen, Germany

²⁹ Radiotherapy I, The Oncology Institute ‘Prof. Dr. Ion Chiricuta’, Cluj-Napoca34-36 Republicii Street, RO-400015, Romania

³⁰ Department of Radiology Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Cracow Branch, Cracow, Poland

states of the European Union, there were 361,608 new BC cases in 2012 and these are estimated to have increased to 373,733 in 2015 (+3.4 %); deaths were 91,585 and 95,357, respectively (+4.1 %) [1]. No major differences in this trend can be appreciated across European countries.

Notwithstanding its intrinsic limitations in terms of sensitivity and specificity, mammography remains the main tool for population-based mass screening with demonstrated effectiveness in reducing mortality and allowing for conservative treatment, as already stated by EUSOBI [2]. Tumour stage at diagnosis of BC still significantly impacts on overall survival even in the current era of effective systemic therapy. Thus, early diagnosis remains crucial. This principle has been recently confirmed by an interesting population-based study from the Netherlands Cancer Registry, which evaluated more than 170,000 BC patients. The proportion of patients receiving neoadjuvant/adjuvant systemic therapy increased from 53 % in 1995–2005 to 60 % in 2006–2012. However, in 2006–2012 the mortality for larger tumours remained greater than that for smaller tumours, significantly for the comparison of T1c and T1a stage, and was independent from nodal status [3].

The evidence in favour of screening mammography has been recently summarized by the International Agency for Research on Cancer (IARC) [4]. Upon randomized controlled trials, the reduction in BC mortality due to screening mammography is confirmed for women between 50 and 69 years of age. Considering 20 cohort studies and 20 case-control studies, the estimated reduction in BC mortality is 40 % for women aged 50–69 years who take up the invitation and

23 % when also including those who do not accept the invitation, as a societal effect of the screening policy. From cohort studies, a mortality reduction has also been estimated for women aged 40–49 years and 70–74 years, though the evidence from published studies was considered to be “limited”. Available data did not allow the IARC working group to define an optimal screening interval. However, we should consider that the majority of European countries opted for biennial screening in the 50- to 69-year-old cohort. When 40- to 49-year-old cohort is invited, the yearly interval is generally adopted in consideration of a potential higher speed of BC growth and of a lower sensitivity of mammography due to the higher breast density.

The average cumulative risk for a false-positive recall in organized screening programmes has been evaluated by the IARC working group to be about 20 % for women aged 50–69 years who have ten screens in 20 years, while the needle biopsy rate for a false-positive finding is lower than 1 % per round [4]. In addition, it should be noted that screening mammography allows for both downscaling clinico-pathological features of invasive BCs and reducing the impact of loco-regional and adjuvant treatments [5–8].

With regard to overdiagnosis (i.e. the rate of screen-diagnosed BCs otherwise unnoticed during the patient’s lifetime), the IARC working group accepted the estimate provided by the Euroscreen working group [9], equal to 6.5 % (range 1–10 %), which was calculated on the basis of the difference in the cumulative probability of a BC diagnosis among women receiving or not receiving screening mammography, taking

³¹ Department of Radiology, Radboud University Nijmegen Medical Centre, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands

³² Department of Radiology/Breast Imaging, Instituto Português de Oncologia de Lisboa, Rua Professor Lima Basto, 1099-023 Lisboa, Portugal

³³ U.O. Radiagnostica, Candiolo Cancer Institute - FPO, IRCCS, Str. Prov. 142, km 3.95, 10060, Candiolo, Turin, Italy

³⁴ Genitourinary Radiology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium

³⁵ Klinik für Radiologie, Neuroradiologie & Nuklearmedizin, Klinikum Frankfurt Höchst, Frankfurt, Germany

³⁶ Diagnoscan, SZTE Radiológiai Klinika, Szeged, Semmelweis u. 6, 6725 Szeged, Hungary

³⁷ Breast Imaging Unit, Scientific Institute (IRCCS) Ospedale San Raffaele, Via Olgettina, 60, 20132 Milan, Italy

³⁸ Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Viale Regina Elena, 324, 00161 Rome, Italy

³⁹ Department of Imaging, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

⁴⁰ Department of Diagnostic Radiology, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland

⁴¹ Department of Radiology and Medical Imaging, State University of Medicine and Pharmacy ‘Nicolae Testemitanu’, bul. St. cel Mare 165, Chisinau MD 2012, Moldova

⁴² Italian Group for Mammographic Screening (GISMa); Senology Unit, Local Health Authority, Bologna, Italy

⁴³ Marlene Greenebaum Diagnostic Breast Center, Department of Radiology, Hadassah Hebrew University Hospital, Hadassah Ein Kerem Medical Center, 91120 Jerusalem, Israel

⁴⁴ Clinic of Radiology, Alexander Dubček University of Trenčín in Trenčín, Faculty of Healthcare, Študentská 2, 911 50, Trenčín, Slovakia

⁴⁵ Radiology Centre, North Estonia Medical Centre, 19 Sütiste Street, 13419 Tallinn, Estonia

⁴⁶ Department of Radiology, Hôpital Lapeyronie, 371 Av. du Doyen Gaston Giraud, 34295 Montpellier, France

⁴⁷ Department of Radiology, Rigshospitalet Blegdamsvej and Glostrup, Mammography Screening Programme in Capital Region, Blegdamsvej 9, 2100 Copenhagen, Denmark

⁴⁸ Diagnostic Mammography Center, Kifisias 362, Chalandri 15233, Athens, Greece

⁴⁹ Duna Medical Center, Lechner Ödön fasor 7, 1095 Budapest, Hungary

Table 1 List of 30 national breast radiology bodies who signed a Memorandum of Understanding with the European Society of Breast Imaging and co-authored this paper

Austria	WG on Breast Imaging, Austrian Roentgen Society, Österreichische Röntgengesellschaft (ÖRG)
Belgium	Senology Section of the Belgian Society of Radiology
Bosnia and Herzegovina	Association of Radiology of Bosnia and Herzegovina
Bulgaria	Bulgarian Society of Breast Imaging
Croatia	Croatian Society of Radiology Working Group of Breast
Czech Republic	Association of Czech Breast Radiologists
Denmark	Danish Society of Breast Imaging
Estonia	Breast Imaging Subgroup of Estonian Society of Radiology
Finland	Radiological Society of Finland/Breast Radiologists of Finland
France	Société d'Imagerie de la Femme (SIFEM)
Germany	AG Mammadiagnostik / Breast Imaging Working Group of the German Roentgen Society
Greece	Hellenic Breast Imaging Society
Hungary	Section of Breast Diagnostics, Hungarian Society of Radiologists
Iceland	The Breast Imaging Group of The Radiological Society of Iceland
Ireland	Irish Breast Radiology Group
Israel	Israel Breast Imaging Society
Italy	Italian College of Breast Radiologists by SIRM (Società Italiana di Radiologia Medica)
Lithuania	Lithuanian Radiology Association
Moldova	Department of Breast Imaging in the Society of Imagists of the Republic of Moldova
The Netherlands	Dutch College of Breast Imaging (DCBI)
Norway	Norwegian Society of Breast Imaging
Poland	Sekcja Diagnostyki Obrazowej Chorób Piersi; Polskie Towarzystwo Radiologiczne
Portugal	Breast Imaging Section of Portuguese Society of Radiology and Nuclear Medicine (SPRMN)
Romania	Romanian Society of Breast Imaging
Serbia	School of Breast Imaging
Slovakia	The Section of Breast Imaging of Slovak Radiologic Society
Spain	Spanish Society of Breast Imaging, Sociedad Española de Diagnostico e Intervencionismo de la Mama (SEDIM)
Sweden	Swedish Breast Imaging Society
Switzerland	Breast screening representative of the Swiss Radiological Society
Turkey	Turkish Society of Radiology Breast Imaging Working Group

into account lead time and underlying increasing incidence. If these factors are carefully considered, a similar estimate of overdiagnosis (4–11 %) is also obtained from randomized controlled trials [4]. Notably, while overdiagnosis (resulting from a specific action by the breast radiologist evaluating a finding as suspicious) should be distinguished from overdiagnosis (which also implies an essential role of the pathologist) [10], further efforts should be dedicated to the reduction of the most important negative consequences of overdiagnosis, i.e. overtreatment.

Risk of radiation-induced breast cancer

Radiation-induced BCs from mammography were estimated, based on models including different factors. For the 50- to 69-year age group, taking into account a latency time of 10 years and a dose of 2.5 mGy per screening round, the risk of

radiation-induced BC death has been estimated to be 1 per 100,000 screened women. The risk of radiation-induced BC due to screening mammography is at least 100 times lower than the probability of avoiding a BC death [4]. Applying a mortality reduction rate of 43 %, biennial screening mammography performed in 100,000 women saves 350 lives [11]. For the 40- to 49-year age group, the problem of radiation effects must be more carefully considered and depends on the estimated magnitude of radiation-induced BCs. Importantly, most of radiation-induced BCs will be cured [12].

Screening models

On the basis of the available evidence, the EUSOBI and the above-listed national breast radiology bodies strongly support screening mammography of the female population at average BC risk, typically from 50 to 69 years of age; extension of this

up to 73–75 years, biennially, is a second priority. Extension from 40 or 45–49, with annual screening, can be evaluated as a third priority, country-by-country. Age selection and screening interval should be adapted to national demographics and local priorities. Importantly, these societies strongly discourage the use of methods for screening such as thermography or other optical imaging tools as an alternative to mammography [13]. Moreover, these societies also discourage the use of ultrasound as a primary screening tool in asymptomatic European women at average risk of BC.

Preference should be given to population-based screening programmes on a regional/national basis with double reading rather than spontaneous mammographic screening with a single reading, given the advantages of the former in terms of higher specificity and positive predictive value [14, 15], lower cost, as well as structured quality controls and central data management. This concept has also been recently reinforced by the IARC working group in the above-mentioned paper [4].

In a wider framework, the EUSOBI and the above-listed national breast radiology bodies are aware of the open debate in other contexts such as that in the USA where the Society of Breast Imaging and the American College of Radiology support annual screening mammography from the age of 40 years by informing women on the advantages of early BC diagnosis [16]. The recent recommendations of the American Cancer Society [17] can be a reference for the US context: (1) regular screening mammography starting at age 45 years (strong recommendation); (2) annual screening mammography from 45–54 years of age (qualified recommendation); (3) from 55 years of age, transition to biennial or continuing annually (qualified recommendation); (4) opportunity to begin annual screening from 40–44 years (qualified recommendation); (6) continue screening mammography as long as women's overall health is good and they have a life expectancy of ≥ 10 years (qualified recommendation); (7) no suggestion for screening clinical breast examination at any age (qualified recommendation).

Breast density

The EUSOBI and the above-listed national breast radiology bodies are aware of the masking effect of increased breast density, strongly impacting on the sensitivity of screening mammography, declining from 86–89 % for almost entirely fatty breasts to only 62–68 % for extremely dense breasts [18]. Studies aimed at reducing this negative effect by means of supplemental screening tools, such as manual or automated breast ultrasound, are welcome, especially when evaluating the cost-effectiveness of the additional tools on the large scale of population-based screening programmes. These societies also take into consideration the role of breast density as an independent BC risk factor, although this factor can be over-

rated [19, 20], especially when reported as a communication to the women. In studies with a control group not limited to fatty breasts, the relative risk of women with dense breasts dropped to 2 or less [21, 22]. At any rate, these societies consider the general adoption of direct digital mammography to be the first priority to improve the sensitivity in women with increased breast density.

The potential of digital breast tomosynthesis

These societies also consider the increasing evidence in favour of digital breast tomosynthesis (DBT) as a screening tool. Three prospective studies showed that DBT used as an adjunct [23–25] or alternative [26] to two-dimensional (2D) digital mammography allows for a superior diagnostic performance when compared to the latter alone. Overall, DBT increases the detection rate from 0.5 to 2.7 per 1,000 screened women and reduces the recall rate from 0.8 to 3.6 per 100 screened women [27]. Of note, DBT is now proposed along with synthetic 2D views, practically solving the problem of an increased radiation exposure when DBT is performed as an adjunct to 2D digital mammography [28–30]. All these aspects will probably also confer to DBT the status of future “routine mammography” in the screening setting. However, before introducing DBT in BC screening outside trials approved by ethical committees, we need evidence for a statistically significant and clinically relevant reduction in the interval cancer rate. This cautiousness is due to the need to avoid an increase in overdiagnosis and costs, in the absence of the demonstration of cost-effectiveness of screening DBT (proof of which may require very long studies). First results on a reduction from 0.7 to 0.5 interval cancers per 100 screened women were very recently reported from a large study in the USA [31], but further evidence is needed. Moreover, the probable increase in reading time associated with the use of DBT in screening [32] and its effects on sustainability of screening programmes should be considered before routine implementation.

Preference for digital instead of film-screen mammography

Overall, looking at the course of technological evolution of mammography in the last decades and at the current trend in favour of DBT, these societies strongly support the adoption of direct digital mammography (not phosphor-plate computer radiography) instead of film-screen mammography in all countries. In fact, digital mammography implies many substantial advantages, including lower dose, higher image

quality, possibility of post-processing, digital archiving, image transmission and no chemical pollution. We suggest that new mammographic units should be based on direct digital mammography technology and, when possible, equipped with DBT in readiness for the next evolution.

Need for certified and subspecialty-trained radiologists in the context of breast centres

Screening mammograms, with or without DBT, should be read by radiologists qualified as screening mammography readers. Proficiency tests at the regional/national/European level are encouraged in order to guarantee a standardized reading quality together with minimum screening numbers read per year.

It is essential that there is a continuity of care from screening mammography to diagnostic breast imaging, to needle sampling and treatment planning either in the context of a dedicated breast centre or in a screening centre that has a well-organized relationship with a diagnostic imaging facility. Whenever possible, radiologists should operate in the context of integrated breast units with the help of organized/structured cooperation among BC specialists.

Quality assurance programmes regarding breast radiology units/sections are also encouraged in the context of forthcoming new European guidelines for BC screening, diagnosis and treatment.

Preference for core or vacuum-assisted biopsy

Preference should be given to needle sampling of breast lesions using core biopsy or vacuum-assisted biopsy instead of fine needle aspiration [33], in consideration of the lower false-negative rate and/or inadequate sampling, unless strict cooperation with a cytologist allows for a demonstrable equally high diagnostic performance. This preference does not apply for sampling of lymph nodes suspected to be metastatic at ultrasound of axilla, where fine needle aspiration has been shown to be effective [34].

Women at increased risk for breast cancer

These societies are in favour of including, whenever possible, dedicated pathways for high-risk women (lifetime risk equal to or higher than 20 %), offering magnetic resonance imaging according to national or international guidelines and recommendations [35–37]. In this regard, policies will be different, considering the heterogeneity of health systems across countries. Studies considering risk stratification for different screening strategies of women at increased BC risk are welcome.

Summary statement

EUSOBI and 30 national breast radiology bodies strongly support mammography as a population-based mass screening tool which results in a relevant reduction in BC mortality and leads to a favourable decrease in both loco-regional and adjuvant treatments in women attending these programmes. People and institutions questioning its validity despite a large body of evidence accumulated in more than three decades put women's lives at risk.

Acknowledgements The scientific guarantor of this publication is Francesco Sardanelli. The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. No complex statistical methods were necessary for this paper. Institutional Review Board approval was not required because the presented article is a special report. Methodology: Special report

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Globocan Online Analysis (http://globocan.iarc.fr/Pages/burden_sel.aspx, accessed on June 3, 2016)
2. Sardanelli F, Helbich TH, European Society of Breast Imaging (EUSOBI) (2012) Mammography: EUSOBI recommendations for women's information. *Insights Imaging* 3(1):7–10
3. Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. *BMJ* 351:h4901
4. Lauby-Secretan B, Scoccianti C, Loomis D, International Agency for Research on Cancer Handbook Working Group et al (2015) Breast Cancer Screening – Viewpoint of the IARC Working Group. *N Engl J Med* 372(24):2353–2358
5. Hofvind S, Sørum R, Thoresen S (2008) Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-program. *Acta Oncol* 47(2): 225–231
6. Cutuli B, Dalenc F, Cottu PH et al (2015) Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys. *Cancer Radiother* 19(5):295–302
7. Dong W, Berry DA, Bevers TB et al (2008) Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. *Cancer Epidemiol Biomark* 17(5):1096–1103
8. Nagtegaal ID, Allgood PC, Duffy SW et al (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? *Cancer* 117(7):1360–1368
9. Paci E, EUROSCREEN Working Group (2012) Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. *J Med Screen* 19(Suppl 1):5–13

10. Colin C, Devouassoux-Shisheboran M, Sardanelli F (2014) Is breast cancer overdiagnosis also nested in pathologic misclassification? *Radiology* 273(3):652–655
11. Hauge IH, Pedersen K, Olerud HM, Hole EO, Hofvind S (2014) The risk of radiation-induced breast cancers due to biennial mammographic screening in women aged 50–69 years is minimal. *Acta Radiol* 55(10):1174–1179
12. Yaffe MJ, Mainprize JG (2011) Risk of radiation-induced breast cancer from mammographic screening. *Radiology* 258(1):98–105
13. Brkljčić B, Miletić D, Sardanelli F (2013) Thermography is not a feasible method for breast cancer screening. *Coll Antropol* 37(2):589–593
14. Kemp Jacobsen K, Abraham L, Buist DS et al (2015) Comparison of cumulative false-positive risk of screening mammography in the United States and Denmark. *Cancer Epidemiol* 39(4):656–663
15. Kemp Jacobsen K, O'Meara ES, Key D et al (2015) Comparing sensitivity and specificity of screening mammography in the United States and Denmark. *Int J Cancer* 137(9):2198–2207
16. Society of Breast Imaging. <https://www.sbi-online.org/Portals/0/Position%20Statements/2016/SBI%20ACR%20Response%20to%20USPSTF%20Recommendations.pdf>. Accessed on February 8, 2016
17. Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. *JAMA* 314(15):1599–1614
18. Freer PE (2015) Mammographic breast density: impact on breast cancer risk and implications for screening. *RadioGraphics* 35(2):302–315
19. Colin C, Prince V, Valette PJ (2013) Can mammographic assessments lead to consider density as a risk factor for breast cancer? *Eur J Radiol* 82(3):404–411
20. Colin C, Schott AM, Valette PJ (2014) Mammographic density is not a worthwhile examination to distinguish high cancer risk women in screening. *Eur Radiol* 24(10):2412–2416
21. Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP et al (2016) Comparison of clinical and automated breast density measurements: Implications for risk prediction and supplemental screening. *Radiology* 279(3):710–719
22. McCormack VA, dos Santos SI (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 15(6):1159–1169
23. Skaane P, Bandos AI, Gullien R et al (2013) Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. *Radiology* 267(1):47–56
24. Skaane P, Bandos AI, Gullien R et al (2013) Prospective trial comparing full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening programme using independent double reading with arbitration. *Eur Radiol* 23(8):2061–2071
25. Ciatto S, Houssami N, Bernardi D et al (2013) Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. *Lancet Oncol* 14(7):583–589
26. Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. *Eur Radiol* 26(1):184–190
27. Houssami N (2015) Digital breast tomosynthesis (3D-mammography) screening: data and implications for population screening. *Expert Rev Med Devices* 12(4):377–379
28. Svahn TM, Houssami N, Sechopoulos I, Mattsson S (2015) Review of radiation dose estimates in digital breast tomosynthesis relative to those in two-view full field digital mammography. *Breast* 24(2):93–99
29. Gur D, Zuley ML, Anello MI et al (2012) Dose reduction in digital breast tomosynthesis (TM) screening using synthetically reconstructed projection images: an observer performance study. *Acad Radiol* 19(2):166–171
30. Skaane P, Bandos AI, Eben EB et al (2014) Two-view Digital Breast Tomosynthesis screening with synthetically reconstructed projections images: comparison with digital breast tomosynthesis with full-field digital mammographic images. *Radiology* 271(3):655–663
31. McDonald ES, Oustimov A, Weinstein SP, Synnestvedt MB, Schnall M, Conant EF (2016) Effectiveness of digital breast tomosynthesis compared with digital mammography: Outcomes analysis from 3 years of breast cancer screening. *JAMA Oncol* 2(6):737–743
32. Gilbert FJ, Tucker L, Young KC (2016) Digital breast tomosynthesis (DBT): a review of the evidence for use as a screening tool. *Clin Radiol* 71(2):141–150
33. van Breest SV, Nederend J, Voogd AC et al (2013) Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands. *Br J Cancer* 109(1):242–248
34. Castellano I, Deambrogio C, Muscarà F et al (2014) Efficiency of a preoperative axillary ultrasound and fine-needle aspiration cytology to detect patients with extensive axillary lymph node involvement. *PLoS One* 9(9), e106640
35. Saslow D, Boetes C, Burke W, American Cancer Society Breast Cancer Advisory Group et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 57(2):75–89
36. Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. *Eur J Cancer* 46(8):1296–1316
37. Mann RM, Balleyguier C, Baltzer PA, European Society of Breast Imaging (EUSOBI), with language review by Europa Donna–The European Breast Cancer Coalition et al (2015) Breast MRI: EUSOBI recommendations for women's information. *Eur Radiol* 25(12):3669–3678